The 12 analysts offering 12-month price forecasts for Amicus Therapeutics Inc have a median target of 14.50, with a high estimate of 29.00 and a low estimate of 12.00. The median estimate represents a +64.59% increase from the last price of 8.81.
The current consensus among 14 polled investment analysts is to Hold stock in Amicus Therapeutics Inc. This rating has held steady since July, when it was unchanged from a Hold rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.22
Reporting Date Aug 10
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.